CN102416159A - Chinese medicinal composition for treating rheumatic ostealgia - Google Patents
Chinese medicinal composition for treating rheumatic ostealgia Download PDFInfo
- Publication number
- CN102416159A CN102416159A CN2011104144215A CN201110414421A CN102416159A CN 102416159 A CN102416159 A CN 102416159A CN 2011104144215 A CN2011104144215 A CN 2011104144215A CN 201110414421 A CN201110414421 A CN 201110414421A CN 102416159 A CN102416159 A CN 102416159A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- quintessence oil
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a Chinese medicinal composition for treating rheumatic ostealgia. The composition comprises the following components in parts by weight: 10-50 parts of needle juniper essential oil, 30-100 parts of ginger essential oil, 5-50 parts of borneol and 5-50 parts of camphor. The Chinese medicinal composition has the advantages of quick response, durable effect, convenience for carrying, no pollution on clothes, and the like. The Chinese medicinal composition is applied to auxiliary treatment of protrusion of lumbar vertebral disc, cervical spondylosis, scapulohumeral periarthritis, rheumatism, rheumatoid arthritis, ankylosing spondylitis, sciatica, strain of lumbar muscles, hyperosteogeny, traumatic injury, inflammation and pain caused by trauma, and the like.
Description
Technical field
The invention belongs to the Chinese medicine for external application field, be specifically related to a kind of Chinese medicine composition of treating rheumatic ostalgia.
Background technology
Rheumatism is meant with muscle, arthralgia to be one type of disease of master.The main connective tissue that influences health possibly be that immune system injury causes.Rheumatism refer to then that one big type of cause of disease has nothing in common with each other but common ground for involving joint and surrounding soft tissue, comprise the disease of flesh, ligament, synovial bursa, fascia.Arthropathy has pain outward still with swelling and moving obstacle, is outbreak and alleviates the alternative chronic course of disease.Because patient's blood circulation is obstructed; Cause muscle or organize needed nutrition to carry through blood circulation; Cause patient's muscle to lack nutrition and accelerated ageing becomes stiff; Serious meeting causes patient's muscle and blood vessel atrophy, part patient and the joint can occur and disable depleted with viscera function.The medicine of treating rheumatic ostalgia at present clinically has oral, external.Chinese medicine, chemicals are arranged.But the oral drugs side effect is bigger, and external used medicine then can directly act on the affected part, and is rapid-action, and side effect is little, becomes the first-selected analgesic drug product of extensive patients.But many pollution clothes easily of medicine for external use or persistent period are short, become a big drawback.
Summary of the invention
To the weak point that the existing composition of medicine similar with the present invention exists, the object of the invention aims to provide a kind of easy to use, compositions of being used to treat rheumatic ostalgia.
Pharmaceutical composition of the present invention comprises following substances in parts by weight:
Juniperus rigida Sieb.et Zucc. quintessence oil 10-50 part, Rhizoma Zingiberis Recens quintessence oil 30-100 part, Borneolum Syntheticum 5-50 part, Camphora 5-50 part.
Preferably, the content of effective that comprises of compositions of the present invention is:
Juniperus rigida Sieb.et Zucc. quintessence oil 15-30 part, Rhizoma Zingiberis Recens quintessence oil, 40-70 part, Borneolum Syntheticum 15-30 part, Camphora 8-20 part.
Preferred, the content of effective that compositions of the present invention comprises is:
18 parts of Juniperus rigida Sieb.et Zucc. quintessence oils, 40 parts of Rhizoma Zingiberis Recens quintessence oils, 20 parts of Borneolum Syntheticums, 10 parts of Camphoras.
In the pharmaceutical composition of the present invention, can also add penetrating agent and/or wetting agent.
Described penetrating agent is azone 5-15 part; Preferably, azone 8-13 part; Preferred, 10 parts of azones.
Described wetting agent is glycerol 10-100 part; Preferably, glycerol 30-60 part; Preferred, 50 parts of glycerol.
The substrate of described choice of drug and consumption are: 95% ethanol 50-150 part, polyvinyl alcohol 5-150 part;
Medicine of the present invention can be processed spray, liniment or unguentum.
When medication preparation of the present invention is spray and liniment, select the substrate of following weight portion for use: 110 parts of 95% ethanol, 10 parts of polyvinyl alcohol.
When processing unguentum, substrates quantity is: 95% ethanol 80-130 part, 120 parts of polyvinyl alcohol.
Pharmaceutical composition of the present invention can adopt following method preparation:
(1) Juniperus rigida Sieb.et Zucc. quintessence oil, Rhizoma Zingiberis Recens quintessence oil, Borneolum Syntheticum, Camphora are dissolved in 95% ethanol, and is subsequent use
(2) penetrating agent, wetting agent and substrate adjuvant add in the said mixture, stir, and promptly get.
The present invention can also process preparation by conventional method.For example, can be mixed and made into slow releasing preparation, controlled release preparation, gel, ointment, ointment, cream, suppository, patch or the like with adjuvant on any or more than one pharmaceuticss such as starch, dextrin, lactose, microcrystalline Cellulose, hydroxypropyl methylcellulose, Polyethylene Glycol, magnesium stearate, micropowder silica gel, xylitol, lactose, glucose, glycine, sodium benzoate, mannitol, glycine etc.
Be applied in the affected part during use, treat to form one deck peelable, resilient " film " after the solvent evaporates, discharge the quintessence oil energy gradually simultaneously, play microcirculation improvement, promote blood circulation, lenitive effect.These article are not limited by limbs position size and motion frequency, can arbitrarily smear, and promptly bring into play effect after the film forming.
Product is mainly used in the auxiliary treatment of inflammation that prolapse of lumbar intervertebral disc, cervical spondylosis, scapulohumeral periarthritis, rheumatism, rheumatoid arthritis, ankylosing spondylitis, sciatica, lumbar muscle strain, hyperosteogeny, traumatic injury and wound cause and pain etc.
Test Example
1, data and method
1.1 physical data
64 examples all meet the RA diagnostic criteria that U.S. rheumatism association formulated in 1987.64 examples are divided into treatment group and matched group at random, every group 32 example.Male 9 examples in the treatment group, women 23 examples, 38 years old mean age; The course of disease is the longest 36 months, and is the shortest 12 months; Matched group man 8 examples, women 24 examples, 40 years old mean age, the course of disease is the longest 38 months, and is the shortest 11 months.Clinical manifestation is arthralgia, swelling, pain increase in intensity under coldness.Two groups of patients have comparability at aspect comparing difference not statistically significants such as age, sex, the courses of disease.
1.2 Therapeutic Method
The treatment group is smeared with the pharmaceutical composition of the embodiment of the invention 5 every day 3 times, 15 days courses of treatment.The oral rheumatism tablet of matched group (Shenyang Traditional Chinese Medicine Factory provides), each 3, every day 2 times, oral.15 days courses of treatment.
2, curative effect determinate standard and result
Cure in the recent period: transference cure, tongue arteries and veins recover normal, and physics and chemistry detects index and recovers normal; Symptom disappears basically, and physics and chemistry detects index obviously to be improved; Effectively: sx, physical and chemical index has improvement; Invalid: symptom does not alleviate, and physical and chemical index does not have improvement.
3, statistical method
x
2Check, inspection level P=0.05.
4, result
The result sees table 1
Table 1 medicine of the present invention and the contrast of rheumatism tablet treatment rheumatic ostalgia
| Group | n | Cure in the recent period | Produce effects | Effectively | Invalid | Effective percentage |
| The treatment group | 32 | 12 | 9 | 6 | 5 | 84.38%* |
| Matched group | 32 | 11 | 10 | 7 | 4 | 87.5% |
Compare * P＞0.05 with matched group
Effective 27 examples in 32 examples, total effective rate 84.38% are organized in treatment; Effective 28 examples in matched group 32 examples, total effective rate 87.5%; Two groups of comparing difference not statistically significants (P＞0.05).The result shows that the medicine of the embodiment of the invention 5 has the obvious treatment effect to the treatment rheumatic ostalgia with the matched group ratio.
The specific embodiment
Embodiment 1
Juniperus rigida Sieb.et Zucc. quintessence oil 10g, Rhizoma Zingiberis Recens quintessence oil 30g, Borneolum Syntheticum 5, Camphora 5g, azone 5g, glycerol 10g, 95% ethanol 110g, polyvinyl alcohol 8g processes spray or liniment.
Embodiment 2
Juniperus rigida Sieb.et Zucc. quintessence oil 50g, Rhizoma Zingiberis Recens quintessence oil 100g, Borneolum Syntheticum 5g, Camphora 50g, azone 15g, glycerol 100g, 95% ethanol 110g, polyvinyl alcohol 15g processes spray or liniment.
Embodiment 3
Juniperus rigida Sieb.et Zucc. quintessence oil 15g, Rhizoma Zingiberis Recens quintessence oil 40g, Borneolum Syntheticum 15g, Camphora 8g, azone 8g, glycerol 30g, 95% ethanol 110g, polyvinyl alcohol 10g processes spray or liniment.
Embodiment 4
Juniperus rigida Sieb.et Zucc. quintessence oil 30g, Rhizoma Zingiberis Recens quintessence oil 70g, Borneolum Syntheticum 30g, Camphora 20g, azone 10g, glycerol 50g, 95% ethanol 110g, polyvinyl alcohol 15g processes spray or liniment.
Embodiment 5
Juniperus rigida Sieb.et Zucc. quintessence oil 18g, Rhizoma Zingiberis Recens quintessence oil 40g, Borneolum Syntheticum 20g, Camphora 10g, azone 10g, glycerol 50g, 95% ethanol 110g, polyvinyl alcohol 10g processes spray or liniment.
Embodiment 6
Juniperus rigida Sieb.et Zucc. quintessence oil 30g, Rhizoma Zingiberis Recens quintessence oil 600g, Borneolum Syntheticum 40g, Camphora 30g, azone 10g, glycerol 80g, 95% ethanol 110g, polyvinyl alcohol 10g processes spray or liniment.
Embodiment 7
Juniperus rigida Sieb.et Zucc. quintessence oil 25g, Rhizoma Zingiberis Recens quintessence oil 45g, Borneolum Syntheticum 35g, Camphora 45g, azone 13g, glycerol 45g, 95% ethanol 100g, polyvinyl alcohol 120g processes unguentum.
Embodiment 8
Juniperus rigida Sieb.et Zucc. quintessence oil 45g, Rhizoma Zingiberis Recens quintessence oil 97g, Borneolum Syntheticum 25g, Camphora 15g, azone 7g, glycerol 60g, 95% ethanol 120g, polyvinyl alcohol 120g processes unguentum.
Embodiment 9
Juniperus rigida Sieb.et Zucc. quintessence oil 15g, Rhizoma Zingiberis Recens quintessence oil 55g, Borneolum Syntheticum 30g, Camphora 30g, azone 8g, glycerol 90g, 95% ethanol 110g, polyvinyl alcohol 120g processes unguentum.
Embodiment 10
Juniperus rigida Sieb.et Zucc. quintessence oil 50g, Rhizoma Zingiberis Recens quintessence oil 90g, Borneolum Syntheticum 40g, Camphora 40g, azone 12g, glycerol 75g, 95% ethanol 90g, polyvinyl alcohol 120g processes unguentum.
Embodiment 11
Juniperus rigida Sieb.et Zucc. quintessence oil 10g, Rhizoma Zingiberis Recens quintessence oil 100g, Borneolum Syntheticum 10g, Camphora 20g, azone 10g, glycerol 70g, 95% ethanol 100g, polyvinyl alcohol 120g processes unguentum.
Claims (10)
1. Chinese medicine composition of treating rheumatic ostalgia comprises the composition of following weight portion: Juniperus rigida Sieb.et Zucc. quintessence oil 10-50 part, Rhizoma Zingiberis Recens quintessence oil 30-100 part, Borneolum Syntheticum 5-50 part, Camphora 5-50 part.
2. Chinese medicine composition according to claim 1 is characterized in that, described composition and weight portion are: Juniperus rigida Sieb.et Zucc. quintessence oil 15-30 part, Rhizoma Zingiberis Recens quintessence oil, 40-70 part, Borneolum Syntheticum 15-30 part, Camphora 8-20 part.
3. Chinese medicine composition according to claim 2 is characterized in that, described composition and weight portion are: 18 parts of Juniperus rigida Sieb.et Zucc. quintessence oils, 40 parts of Rhizoma Zingiberis Recens quintessence oils, 20 parts of Borneolum Syntheticums, 10 parts of Camphoras.
4. according to the described Chinese medicine composition of the arbitrary claim of claim 1-3, it is characterized in that, in the described pharmaceutical composition, can also add penetrating agent and/or wetting agent.
5. Chinese medicine composition according to claim 4 is characterized in that, described penetrating agent is azone 5-15 part; Described wetting agent is glycerol 10-100 part.
6. Chinese medicine composition according to claim 5 is characterized in that, described azone 8-13 part; Described glycerol 30-60 part.
7. Chinese medicine composition according to claim 5 is characterized in that, 10 parts of described azones; 50 parts of described glycerol.
8. according to the described Chinese medicine composition of the arbitrary claim of claim 1-7, it is characterized in that described pharmaceutical composition substrate and consumption are 95% ethanol 50-150 part, polyvinyl alcohol 5-150 part.
9. Chinese medicine composition according to claim 8 is characterized in that, when described medicine is processed spray or liniment, selects the substrate of following weight portion for use: 110 parts of 95% ethanol, 10 parts of polyvinyl alcohol.
10. Chinese medicine composition according to claim 8 is characterized in that, when described medicine is processed unguentum, selects the substrate of following weight portion for use: 95% ethanol 80-130 part, 120 parts of polyvinyl alcohol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104144215A CN102416159A (en) | 2011-12-13 | 2011-12-13 | Chinese medicinal composition for treating rheumatic ostealgia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104144215A CN102416159A (en) | 2011-12-13 | 2011-12-13 | Chinese medicinal composition for treating rheumatic ostealgia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102416159A true CN102416159A (en) | 2012-04-18 |
Family
ID=45940960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104144215A Pending CN102416159A (en) | 2011-12-13 | 2011-12-13 | Chinese medicinal composition for treating rheumatic ostealgia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102416159A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105943985A (en) * | 2016-06-22 | 2016-09-21 | 周金盆 | Traditional Chinese medicine composition for treating rheumatic pain |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
| CN102049090A (en) * | 2010-12-20 | 2011-05-11 | 傅金龙 | Moxibustion patch and preparation method thereof |
-
2011
- 2011-12-13 CN CN2011104144215A patent/CN102416159A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
| CN102049090A (en) * | 2010-12-20 | 2011-05-11 | 傅金龙 | Moxibustion patch and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 周小雅: "中药冰片的药理研究", 《中国现代应用药学杂志》, 30 June 1998 (1998-06-30) * |
| 尹庆林等主编: "《香皂精油》", 31 January 2010, article "香皂精油" * |
| 李俊等: "舒活软膏的制备和疗效观察", 《中国医院药学杂志》, 31 December 1998 (1998-12-31) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105943985A (en) * | 2016-06-22 | 2016-09-21 | 周金盆 | Traditional Chinese medicine composition for treating rheumatic pain |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Berlanga et al. | Heberprot-P: a novel product for treating advanced diabetic foot ulcer | |
| CN103282021A (en) | Inflammatory disease | |
| CN103191284A (en) | Dragon blood spraying film agent applied to superficial wound and preparation technology thereof | |
| WO2016094732A1 (en) | METHODS OF TREATING PAIN AND/OR ITCH WITH SMALL MOLECULE INHIBITORS TARGETING AN mTOR PATHWAY | |
| JP2019081755A (en) | Composition | |
| CN102949450B (en) | Nux vomica alkaloid patch for treating local myalgia and arthralgia and preparation method | |
| CN102416159A (en) | Chinese medicinal composition for treating rheumatic ostealgia | |
| CN101310734A (en) | Chinese and western combine compound uterus perfusate for treating cow endometritis | |
| JP6778200B2 (en) | Compositions Containing Spiranthes sinensis Extract and Pharmaceutical Applications thereof | |
| CN105147642B (en) | A kind of transdermal patch containing Formoterol or its fumarate | |
| CN114869902B (en) | Pharmaceutical composition containing tretinoin and geniposide for treating psoriasis | |
| CN102784157B (en) | The purposes of Gracillin and the pharmaceutical composition containing Gracillin | |
| US20240024273A1 (en) | Topical administration of 2-(diethylamino)ethyl 2-(4-isobutylphenyl)proprionate for treatment of diseases | |
| WO2023092644A1 (en) | Composition having analgesic effect and application of composition, and microneedle patch and preparation method therefor | |
| WO2018161890A1 (en) | Application of berberine in preparing drug for treating acute soft tissue injury | |
| CN1251707C (en) | Treatment of arthritis and other similar conditions | |
| CN103784942A (en) | Application of artesunate and ulinastatin in combined treatment of pancreatitis | |
| CN102008536B (en) | Tripterygium wilfordii hook extract cataplasm and preparation method thereof | |
| CN105381470A (en) | Modified genistein and application thereof | |
| CN112773786B (en) | Application of icariin in preparation of psoriasis treatment medicine | |
| WO2017181977A1 (en) | Mussel adhesive protein product and use thereof for inhibiting soft tissue inflammation | |
| CN105748427B (en) | A kind of Topiroxostat enteric coatel tablets and preparation method thereof | |
| WO2011076596A1 (en) | A combination for the treatment of osteoarthritis | |
| CN104288368B (en) | A kind of externally applied spray for treating seasonly cutaneous itching disease | |
| CN115040501B (en) | Application of cis-13-octadecenoic acid or salt compound thereof in preparation of drugs for promoting healing of damaged skin and/or mucous membrane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120418 |